SGLT2 inhibitors and the cardiorenal continuum: a paradigm shift in the treatment of patients with T2D
Keywords:
Type 2 diabetes
SGLT2 inhibitors
Cardiorenal
Cardiovascular disease
Kidney disease
Heart failure
Morbidity
Mortality
Chronic kidney disease
Cardiorenal continuum
Note:
This article is licensed under a
Creative Commons Attribution-NonCommer-
cial 4.0 International License
Citation:
Escalada-San Martín, F. (Francisco Javier). "SGLT2 inhibitors and the cardiorenal continuum: a paradigm shift in the treatment of patients with T2D". Diabetes therapy. 13 (Supl. 1), 2022, 1 - 3
Statistics and impact
0 citas en
0 citas en
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.